| Literature DB >> 35513723 |
Constance Baer1, Shunsuke Kimura2, Mitra S Rana3, Andrew B Kleist4,5, Tim Flerlage6, David J Feith7,8, Peter Chockley9, Wencke Walter1, Manja Meggendorfer1, Thomas L Olson7,8, HeeJin Cheon7,8,10, Kristine C Olson7,8, Aakrosh Ratan7,10,11, Martha-Lena Mueller1, James M Foran12, Laura J Janke13, Chunxu Qu13, Shaina N Porter14, Shondra M Pruett-Miller14, Ravi C Kalathur3, Claudia Haferlach1, Wolfgang Kern1, Elisabeth Paietta15, Paul G Thomas16, M Madan Babu17, Thomas P Loughran7,8, Ilaria Iacobucci18, Torsten Haferlach19, Charles G Mullighan20,21.
Abstract
Chronic lymphoproliferative disorder of natural killer cells (CLPD-NK) is characterized by clonal expansion of natural killer (NK) cells where the underlying genetic mechanisms are incompletely understood. In the present study, we report somatic mutations in the chemokine gene CCL22 as the hallmark of a distinct subset of CLPD-NK. CCL22 mutations were enriched at highly conserved residues, mutually exclusive of STAT3 mutations and associated with gene expression programs that resembled normal CD16dim/CD56bright NK cells. Mechanistically, the mutations resulted in ligand-biased chemokine receptor signaling, with decreased internalization of the G-protein-coupled receptor (GPCR) for CCL22, CCR4, via impaired β-arrestin recruitment. This resulted in increased cell chemotaxis in vitro, bidirectional crosstalk with the hematopoietic microenvironment and enhanced NK cell proliferation in vivo in transgenic human IL-15 mice. Somatic CCL22 mutations illustrate a unique mechanism of tumor formation in which gain-of-function chemokine mutations promote tumorigenesis by biased GPCR signaling and dysregulation of microenvironmental crosstalk.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35513723 PMCID: PMC9117519 DOI: 10.1038/s41588-022-01059-2
Source DB: PubMed Journal: Nat Genet ISSN: 1061-4036 Impact factor: 41.307